In draft guid­ance, NICE fails to back Clo­vis's PARP in­hibitor Rubra­ca

De­spite the EMA’s en­dorse­ment of Clo­vis’s can­cer treat­ment Rubra­ca last year, the UK’s cost-ef­fec­tive­ness watch­dog NICE has rec­om­mend­ed against the adop­tion of the drug in the Na­tion­al Health Ser­vice (NHS).

Rubra­ca is ap­proved for use in the EU as monother­a­py for the main­te­nance treat­ment of adult pa­tients with high-grade ep­ithe­lial ovar­i­an, fal­lop­i­an tube, or pri­ma­ry peri­toneal can­cer who have re­lapsed af­ter  plat­inum-based chemother­a­py. The drug was orig­i­nal­ly de­vel­oped at New­cas­tle Uni­ver­si­ty, with a team in­volv­ing re­searchers from the North­ern In­sti­tute for Can­cer Re­search and Can­cer Re­search UK-fund­ed sci­en­tists. It gen­er­at­ed sec­ond-quar­ter sales of $33 mil­lion glob­al­ly.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.